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EDITORIALS
Should Antiviral Treatment Be Extended to Patients
with Chronic Hepatitis B and Mildly Elevated Alanine
Aminotransferase?
See Article on Page 1185.
The availability of seven approved therapies, in-cluding five oral drugs, for chronic hepatitis B hasexpanded the indications for treatment. The de-
cision to initiate treatment is easy in patients with liver
failure, but there continues to be debate regarding when
treatment should be initiated in patients with precirrhotic
liver disease.1,2 Recognizing that liver biopsy is not per-
formed on all patients with chronic hepatitis B, the guide-
lines of the American Association for the Study of Liver
Diseases (AASLD)3,4 and the Asian Pacific Association for
the Study of the Liver (APASL)5 primarily rely on alanine
aminotransferase (ALT) levels to guide treatment deci-
sions. The AASLD and APASL guidelines recommend
treatment for patients with an ALT level higher than 2
times the upper limit of normal (ULN) range and liver
biopsy to guide treatment decisions for patients with an
ALT level 1 to 2 times ULN, particularly if they are above
the age of 40 years. The guidelines of the European Asso-
ciation for the Study of the Liver place more emphasis on
liver histology; they recommend treatment for patients
with at least a Metavir activity grade of A2 (range  0-3)
or a Metavir fibrosis score of F2 (range  0-4).6 All three
guidelines recommend that patients who are deemed not
to be treatment candidates at presentation be monitored
so that treatment can be initiated later when the liver
disease becomes more active.
Many investigators have challenged the recommenda-
tion to defer treatment in patients with normal or mildly
elevated ALT levels. These experts cite recent studies find-
ing that up to 50% of hepatitis B carriers with normal
levels of ALT may have histologically significant liver dis-
ease; however, many of the studies involved small num-
bers of patients, most studies monitored ALT on only one
or two occasions over a 6-month period prior to biopsy,
and all but one study failed to report the number of pa-
tients with normal levels of ALT that were not biopsied.
Thus, the findings of these studies may not be generalized
to patients with persistently normal levels of ALT. For
example, Kumar et al.7 reported that 21% of hepatitis B e
antigen (HBeAg)–negative patients with persistently nor-
mal ALT levels and hepatitis B virus (HBV) DNA levels
below 5 log10 copies/mL had histologically active liver
disease, but only 29 of 75 patients (39%) who met the
ALT and HBV DNA criteria underwent liver biopsy.
Furthermore, the conclusion that a fair proportion of “in-
active carriers” had histologically significant liver disease
was based on the findings of six patients who had a max-
imum fibrosis score of 1 (in a range of 0-4) and a maxi-
mum histology activity index of 5 (in a range of 0-18). In
another study, 59 patients who had normal levels of ALT
on at least two occasions 6 months apart underwent liver
biopsy; 18% had significant fibrosis (Metavir score  F2),
and 34% had significant inflammation (Metavir score 
A2).8 It should be noted that only patients with HBV
DNA levels  4 log10 copies/mL were biopsied, and
age  40 years was an important predictor of significant
liver disease. In a third study, 24 of 69 patients (35%)
with ALT levels 1 to 2 times ULN had significant liver
disease as defined by a fibrosis stage  2 (range  0-4) or
fibrosis stage 1 and an inflammation grade  2 (range 
0-4).9 Age  35 years, male gender, and increasing ALT
levels were predictors of significant liver disease.
Studies that have focused on patients in the immune-
tolerant phase have shown that hepatic inflammation and
fibrosis are negligible to mild in most patients with min-
imal or no progression after 5 years. In one study of 40
patients, 20 had a Metavir fibrosis score of F0, and 20 had
a score of F1; 9 had a Metavir activity score of A0, 29 had
a score of A1, and only 2 had a score of A2.10 In another
study of 57 patients, 19 had an Ishak fibrosis score of 0
(range  0-6), and 38 had stage 1 fibrosis.11 Follow-up
biopsies after a mean of 5 years revealed no changes in the
fibrosis scores for 42 of 48 patients who remained in the
immune-tolerant phase.
These findings indicate that significant liver disease can
be found in HBV carriers with normal ALT levels, but the
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likelihood is low in those with persistently normal ALT
levels, particularly if they are younger than 35 or 40 years
or have serum HBV DNA levels below 4 log10 copies/mL.
In this issue of HEPATOLOGY, Wu et al.12 report a ret-
rospective analysis of the liver histology and treatment
response in a subset of patients who participated in the
phase III clinical trials of entecavir in nucleoside-naı̈ve
patients with chronic hepatitis B. All the patients had at
least one ALT measurement 1.3 to 10 times ULN during
the 12 weeks prior to screening, an ALT measurement 1.3
to 2 times ULN at screening and at the baseline visit, and
a liver biopsy with findings of chronic hepatitis. A total of
336 patients (190 HBeAg-positive patients and 146
HBeAg-negative patients), comprising 25% of the study
population, met these criteria. They found that clinically
significant necroinflammation, defined as a Knodell
necroinflammatory score  7 (range  0-18), was present
in 60% of HBeAg-positive patients and in 72% of
HBeAg-negative patients, and marked fibrosis, defined as
an Ishak fibrosis score  4 (range  0-6), was observed in
8% of HBeAg-positive patients and in 15% of HBeAg-
negative patients. The high percentage of patients with
“mildly elevated ALT at baseline” who had significant
necroinflammation or marked fibrosis is surprising and is
likely related to the criteria used for selecting this subset of
patients. Thus, these patients not only had ALT levels 1.3
to 2 times ULN on two occasions (the screening and
baseline visits), but they also had at least one ALT mea-
surement 1.3 to 10 times ULN prior to screening and an
HBV DNA level  3,000,000 Eq/mL (for HBeAg-posi-
tive patients) or  700,000 Eq/mL (for HBeAg-negative
patients). Because of discrepancies in the Results and Dis-
cussion sections, it is unclear how many of these patients
had ALT levels 1.3 to 2 times ULN and how many had
ALT levels 2 to 10 times ULN prior to screening. Of
greater importance is the requirement for evidence of
chronic hepatitis on liver biopsy as an entry criterion for
these trials. This criterion was necessary because the pri-
mary efficacy endpoint of these trials was histological re-
sponse (defined as an improvement in the Knodell
necroinflammatory score of at least 2 points and no wors-
ening of the fibrosis score). It is not clear how many pa-
tients with ALT levels 1.3 to 2 times ULN at screening
were excluded because of a “low” necroinflammatory
score on baseline biopsy that would have precluded an
assessment of histological response. Therefore, the find-
ing that a high percentage of patients with mildly elevated
ALT levels have significant liver disease on biopsy cannot
be generalized to other patients with ALT levels 1.3 to 2
times ULN on one occasion or ALT levels persistently
within 1.3 to 2 times ULN during follow-up or to pa-
tients with lower HBV DNA levels.
Wu et al.12 noted that, compared to patients with base-
line ALT levels  2 times ULN, HBeAg-negative patients
with baseline ALT levels 1.3 to 2 times ULN who received
entecavir had slightly lower rates of histological improve-
ment (66% versus 72%), HBV DNA suppression (86%
versus 91%), and ALT normalization (76% versus 78%)
at week 48, but these differences were not significant. By
contrast, HBeAg-positive patients with baseline ALT lev-
els 1.3 to 2 times ULN who received entecavir had signif-
icantly lower rates of all responses at week 48 in
comparison with those with baseline ALT levels  2 times
ULN: 62% histological improvement versus 75% (P 
0.001), 48% HBV DNA suppression versus 73% (P 
0.001), 55% ALT normalization versus 73% (P 
0.001), and 8% HBeAg seroconversion versus 26% (P 
0.001).
These data extend the results of previous studies show-
ing that both interferon and nucleos(t)ide analogues are
less efficacious in patients who are in the immune-tolerant
phase13 and support the recommendations that HBeAg-
positive patients with ALT levels 1 to 2 times ULN should
be monitored and that those with ALT levels persistently
in this range should undergo liver biopsy to guide treat-
ment decisions. Although Wu et al.12 showed that antivi-
ral therapy can result in viral suppression and histological
improvement, responses were assessed at week 48 while
the patients were undergoing treatment. Long-term (mul-
tiyear and possibly lifelong) treatment will be necessary
for many of these patients to maintain the responses.
Therefore, until data supporting a benefit of antiviral
therapy for clinical outcomes become available, initiating
every chronic hepatitis B patient with mildly elevated
ALT levels is not warranted. Some of these patients will
turn out to have mild liver disease on biopsy, and others,
notably young HBeAg-positive patients, may undergo
spontaneous HBeAg seroconversion and enter into remis-
sion (at least temporarily) during the next few years.
As our knowledge about the natural history of chronic
HBV infection improves and new and better treatments
become available, it is appropriate to regularly review the
indications for treatment. The Hepatitis B Research Net-
work, sponsored by the National Institute of Diabetes
and Digestive and Kidney Diseases, will be conducting
clinical trials in patients with mild liver disease. Until data
from these trials become available, the decision to initiate
treatment in chronic hepatitis B patients with mildly ele-
vated ALT levels should be individualized.
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